Safety and Efficacy of Alectinib in the First Line for ALK-Mutated Lung Cancer: A Real-World Data from India

Safety and Efficacy of Alectinib in the First Line for ALK-Mutated Lung Cancer: A Real-World Data from India

Saved in:

Bibliographic Details
Main Authors:	Ajaykumar Singh, Vanita Noronha, Vijay Patil, Nandini Menon, Akhil Kapoor, Mehak Trikha, Sima Manmode, Rajiv Kaushal, Trupti Pai, Nilendu Purandare, Amit Janu, Anuradha Majumdar, Ahmad Ashfaq Ahmad Ubharay, Kumar Prabhash
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd.
Series:	South Asian Journal of Cancer
Subjects:	alectinib ALK anaplastic lymphoma kinase LMIC low- and middle-income countries OS overall survival PFS progression-free survival
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0045-1806811
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
by: Naoko Imanishi, et al.
Published: (2018-03-01)

Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient
by: Kaili Huang, et al.
Published: (2025-04-01)

Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review
by: Hongxia Wang, et al.
Published: (2025-01-01)

Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review
by: Huang Chen, et al.
Published: (2024-12-01)

Lorlatinib overcomes alectinib‐induced hemolytic anemia in an ALK fusion positive non‐small‐cell lung cancer patient with severe tumor‐associated liver failure: A case report
by: Kei Kunimasa, et al.
Published: (2024-12-01)

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib
by: Feng Jin, et al.
Published: (2025-06-01)

The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis
by: Luca Mastrantoni, et al.
Published: (2024-01-01)

CLINICAL EFFICACY OF TARGETED THERAPY TOWARDS METASTATIC LUNG CANCER CARRYING DISTINCT TYPES OF ALK REARRANGEMENTS
by: N. V. Mitiushkina, et al.
Published: (2020-09-01)

Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada
by: Lara Chayab, et al.
Published: (2024-12-01)

Case Report: Locally advanced lung adenocarcinoma with a novel MIR217HG-ALK rearrangement responding to neoadjuvant alectinib
by: Yinyin Xue, et al.
Published: (2025-08-01)

Successful treatment of a non‐small‐cell lung cancer patient harboring HIP1‐ALK (H28:A20) and CTNNB1 p.S45del with alectinib
by: Vito Longo, et al.
Published: (2024-11-01)

Partial response to treatment with ALK inhibitor in a patient with SQSTM1-ALK fusion positive lung adenocarcinoma
by: Brenda Paola Rodriguez Arroyo, et al.
Published: (2024-11-01)

Perforation of the descending colon induced by alectinib in a patient with non-small cell lung cancer: a Case Report
by: Yun Li, et al.
Published: (2025-05-01)

Alectinib-Induced Hemolysis in a Case of ALK-Positive Metastatic Lung Adenocarcinoma: A Case Report with Review of Literature
by: Suparna Ajit Rao, et al.

Case Report: Ocular metastasis from ALK-rearranged pulmonary adenocarcinoma presenting as a pseudo-syndrome of anterior uveitis
by: Cong Zhao, et al.
Published: (2025-08-01)

Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC
by: Ceva Wicaksono Pitoyo, et al.
Published: (2022-07-01)

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
by: Hiroshi Hashimoto, et al.
Published: (2022-04-01)

Modern treatment of ALK-positive non-small cell lung cancer
by: D. A. Kharagezov, et al.
Published: (2022-06-01)

Safety of brigatinib following alectinib-induced-pneumonitis: Case report
by: Blerina Resuli, et al.
Published: (2025-01-01)

Venous thromboembolism is associated with increased all-cause mortality in ALK-positive non-small cell lung cancer
by: Magdalena Zaborowska-Szmit, et al.
Published: (2024-11-01)

PFS24 as a prognostic milestone in patients with newly diagnosed primary CNS lymphoma
by: Vanja Zeremski, et al.
Published: (2025-04-01)

Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study
by: A. S. Kolbin, et al.
Published: (2023-11-01)

Cost‐Effectiveness Analysis of Adjuvant Alectinib versus Platinum‐Based Chemotherapy in Resected ALK‐Positive Non‐Small‐Cell Lung Cancer in the Chinese Health Care System
by: Qiran Wei, et al.
Published: (2024-11-01)

Chemometrically assisted optimization and validation of the HPLC method for the analysis of alectinib and its related impurity with measurement uncertainty evaluation and whiteness, blueness, and greenness profile assessments
by: Serkan Levent, et al.
Published: (2025-05-01)

Alectinib-Loaded Chitosan–Alginate Nanoparticles: A Novel Synthesis Method with In Vitro and In Vivo Evaluations
by: Tha’er Ata, et al.
Published: (2025-04-01)

Magnesium Isoglycyrrhizinate Alleviates Alectinib-Induced Hepatotoxicity by Inhibiting Mitochondrial Damage-Mediated Pyroptosis
by: Chen Y, et al.
Published: (2025-07-01)

A novel double fusion of EML4-ALK and PLEKHA7-ALK contribute to rapid progression of lung adenocarcinoma: a case report and literature review
by: Zhongzhao Wang, et al.
Published: (2024-11-01)

Prognosis of Tyrosine Kinase Inhibitor Therapy for Non-Small Cell Lung Cancer
by: Agus Andreas Santoso, et al.
Published: (2025-05-01)

Lung Adenocarcinoma Expressing an EML4‐ALK Fusion Transcript With Premature Stop Codons and Response to Alectinib: A Case Report
by: Mami Ozaki, et al.
Published: (2025-08-01)

Middle‐Out Physiologically Based Pharmacokinetic Modeling to Support Pediatric Dosing Recommendation for Alectinib
by: Tamara vanDonge, et al.
Published: (2025-06-01)

Design, synthesis and biological evaluation of 2,4-pyrimidinediamine derivatives as ALK and HDACs dual inhibitors for the treatment of ALK addicted cancer
by: Dafeng Guo, et al.
Published: (2022-12-01)

Long-term outcomes of induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
by: Xiaoyan Zhao, et al.
Published: (2024-11-01)

Successful recovery of 85% TBSA burns in a resource-limited Nigerian hospital without a burns ward or intensive care unit: A case report
by: Innih Asuekome Kadiri, et al.
Published: (2025-04-01)

Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma
by: Seema Chugh, et al.
Published: (2025-02-01)

The GntR/VanR transcription regulator AlkR represses AlkB2 monooxygenase expression and regulates n‐alkane degradation in Pseudomonas aeruginosa SJTD‐1
by: Wanli Peng, et al.
Published: (2025-04-01)

Efficacy and safety of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: a systematic review and updated meta-analysis
by: Ahmad Azhar Marzuqi, et al.
Published: (2025-04-01)

Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years
by: Si Yu Lin, et al.
Published: (2024-07-01)

Corrigendum: Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years
by: Si Yu Lin, et al.
Published: (2025-03-01)

Mechanisms of Resistance to ALK Inhibitors and Corresponding Treatment Strategies in Lung Cancer
by: Xie J, et al.
Published: (2025-04-01)

Global research trends on ALK-TKIs in non-small cell lung cancer: a bibliometric analysis
by: Yafeng Liu, et al.
Published: (2025-08-01)